CL2007003705A1 - Compuestos derivados de nicotinamida; composicion farmaceutica; y uso para tratar una enfermedad o afeccion mediada al menos en parte por prostaglandina d2 producida por h-pgds tal como alergia o inflamacion alergica y asma. - Google Patents
Compuestos derivados de nicotinamida; composicion farmaceutica; y uso para tratar una enfermedad o afeccion mediada al menos en parte por prostaglandina d2 producida por h-pgds tal como alergia o inflamacion alergica y asma.Info
- Publication number
- CL2007003705A1 CL2007003705A1 CL200703705A CL2007003705A CL2007003705A1 CL 2007003705 A1 CL2007003705 A1 CL 2007003705A1 CL 200703705 A CL200703705 A CL 200703705A CL 2007003705 A CL2007003705 A CL 2007003705A CL 2007003705 A1 CL2007003705 A1 CL 2007003705A1
- Authority
- CL
- Chile
- Prior art keywords
- pgds
- affection
- nicotinamide
- prostaglandin
- allergy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87077706P | 2006-12-19 | 2006-12-19 | |
| US89165007P | 2007-02-26 | 2007-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003705A1 true CL2007003705A1 (es) | 2008-06-27 |
Family
ID=39523704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703705A CL2007003705A1 (es) | 2006-12-19 | 2007-12-19 | Compuestos derivados de nicotinamida; composicion farmaceutica; y uso para tratar una enfermedad o afeccion mediada al menos en parte por prostaglandina d2 producida por h-pgds tal como alergia o inflamacion alergica y asma. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7902373B2 (enExample) |
| EP (1) | EP2129660A2 (enExample) |
| JP (1) | JP2010513458A (enExample) |
| AR (1) | AR064389A1 (enExample) |
| CA (1) | CA2672373C (enExample) |
| CL (1) | CL2007003705A1 (enExample) |
| PE (1) | PE20081385A1 (enExample) |
| TW (1) | TW200833675A (enExample) |
| UY (1) | UY30804A1 (enExample) |
| WO (1) | WO2008075172A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| WO2008104869A1 (en) | 2007-02-26 | 2008-09-04 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CA2722420A1 (en) | 2008-05-13 | 2009-11-19 | Cayman Chemical Company, Incorporated | Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin d synthase |
| JP2011524894A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| EP2307377A1 (en) | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| AU2009292931B2 (en) * | 2008-09-22 | 2014-09-11 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| JP5706834B2 (ja) * | 2009-03-10 | 2015-04-22 | コーニンクレッカ フィリップス エヌ ヴェ | 喘息の診断 |
| CA2754509C (en) | 2009-03-18 | 2018-03-06 | Resverlogix Corp. | Novel anti-inflammatory agents |
| CN102666508A (zh) | 2009-10-08 | 2012-09-12 | 赛诺菲 | 作为前列腺素d合酶抑制剂的苯基噁二唑衍生物 |
| DE112010005848B4 (de) * | 2010-09-06 | 2016-03-10 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amidverbindungen |
| JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ａｓｋ１阻害ピロロピリミジン誘導体 |
| CN103930407B (zh) * | 2011-09-12 | 2019-02-26 | 默克专利有限公司 | 用作激酶活性调节剂的氨基嘧啶衍生物 |
| CN104583194A (zh) * | 2012-05-11 | 2015-04-29 | 艾伯维公司 | 作为nampt抑制剂的哒嗪和吡啶衍生物 |
| WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| WO2014175370A1 (ja) * | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| US10045979B2 (en) * | 2014-05-19 | 2018-08-14 | Merial Inc. | Anthelmintic compounds |
| CA2951259A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| CA2958881A1 (en) * | 2014-08-28 | 2016-03-03 | X-Chem, Inc. | Soluble epoxide hydrolase inhibitors and uses thereof |
| SG11201701598PA (en) | 2014-09-10 | 2017-03-30 | Epizyme Inc | Smyd inhibitors |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016144660A1 (en) | 2015-03-09 | 2016-09-15 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| US10457703B2 (en) | 2015-03-31 | 2019-10-29 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CN108430992A (zh) * | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| BR112019006651A2 (pt) | 2016-10-04 | 2019-07-02 | Enanta Pharm Inc | análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| TW201908311A (zh) | 2017-06-13 | 2019-03-01 | 英商葛蘭素史克智慧財產發展有限公司 | 化合物 |
| GB201711234D0 (en) | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
| MX2020002788A (es) | 2017-09-13 | 2020-09-14 | Progenity Inc | Biomarcadores de preeclampsia y sistemas y metodos relacionados. |
| US11299481B2 (en) | 2017-10-20 | 2022-04-12 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| BR112020011889A2 (pt) | 2017-12-13 | 2020-11-24 | Glaxosmithkline Intellectual Property Development Limited | piridinas fundidas que agem como inibidores de h-pgds |
| CN112020363A (zh) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | 烟酰胺核苷氯化物的结晶形式 |
| JP7352294B2 (ja) * | 2018-02-02 | 2023-09-28 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| UY38455A (es) | 2018-11-08 | 2020-05-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) |
| US12240829B2 (en) | 2019-03-20 | 2025-03-04 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| TW202108571A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| US20230339937A1 (en) | 2020-06-19 | 2023-10-26 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| EP4259606A1 (en) * | 2020-12-11 | 2023-10-18 | Intervet International B.V. | Anthelmintic compounds comprising a pyridine structure |
| TWI860849B (zh) | 2021-09-14 | 2024-11-01 | 美商美國禮來大藥廠 | Sstr4促效劑鹽 |
| CA3240926A1 (en) | 2021-12-17 | 2023-06-22 | Sato Pharmaceutical Co., Ltd. | Azaindole derivative inhibiting h-pgds |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000507590A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| AU5530998A (en) | 1996-12-18 | 1998-07-15 | E.I. Du Pont De Nemours And Company | Relatively stable (1,3-disubstitutedimidazol-2-ylidene)-type carbenes |
| DE19744401A1 (de) | 1997-10-08 | 1999-04-15 | Bayer Ag | Verfahren zur Herstellung von Triazolinthion-Derivaten |
| US6395753B1 (en) | 2001-08-30 | 2002-05-28 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| JP4500483B2 (ja) | 2002-03-25 | 2010-07-14 | 独立行政法人科学技術振興機構 | ヒト由来プロスタグランジン合成酵素阻害剤 |
| CA2743341A1 (en) | 2002-07-12 | 2004-01-22 | Japan Science And Technology Agency | Drugs for treating or preventing brain injury and a method of screening the same |
| JP4550353B2 (ja) | 2002-07-24 | 2010-09-22 | 株式会社医薬分子設計研究所 | 造血器型プロスタグランジンｄ２合成酵素阻害剤 |
| US20060229324A1 (en) | 2002-10-03 | 2006-10-12 | Akiko Itai | Quinazolin-4-one derivatives |
| US20060100245A1 (en) * | 2002-12-19 | 2006-05-11 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| WO2004081005A1 (en) | 2003-03-07 | 2004-09-23 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| WO2005009954A2 (en) | 2003-07-23 | 2005-02-03 | Synta Pharmaceuticals, Corp. | Method for modulating calcium ion-release-activated calcium ion channels |
| US20050165028A1 (en) | 2004-01-23 | 2005-07-28 | Norman Mark H. | Vanilloid receptor ligands and their use in treatments |
| WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| PE20070589A1 (es) | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
-
2007
- 2007-12-03 EP EP07859056A patent/EP2129660A2/en not_active Withdrawn
- 2007-12-03 WO PCT/IB2007/003928 patent/WO2008075172A2/en not_active Ceased
- 2007-12-03 JP JP2009542256A patent/JP2010513458A/ja not_active Withdrawn
- 2007-12-03 CA CA2672373A patent/CA2672373C/en not_active Expired - Fee Related
- 2007-12-12 US US11/954,799 patent/US7902373B2/en not_active Expired - Fee Related
- 2007-12-14 PE PE2007001800A patent/PE20081385A1/es not_active Application Discontinuation
- 2007-12-17 AR ARP070105664A patent/AR064389A1/es not_active Application Discontinuation
- 2007-12-18 TW TW096148480A patent/TW200833675A/zh unknown
- 2007-12-18 UY UY30804A patent/UY30804A1/es not_active Application Discontinuation
- 2007-12-19 CL CL200703705A patent/CL2007003705A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080146569A1 (en) | 2008-06-19 |
| CA2672373C (en) | 2011-08-30 |
| JP2010513458A (ja) | 2010-04-30 |
| WO2008075172A3 (en) | 2008-10-02 |
| CA2672373A1 (en) | 2008-06-26 |
| AR064389A1 (es) | 2009-04-01 |
| UY30804A1 (es) | 2008-07-31 |
| US7902373B2 (en) | 2011-03-08 |
| WO2008075172A2 (en) | 2008-06-26 |
| PE20081385A1 (es) | 2008-10-04 |
| TW200833675A (en) | 2008-08-16 |
| EP2129660A2 (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003705A1 (es) | Compuestos derivados de nicotinamida; composicion farmaceutica; y uso para tratar una enfermedad o afeccion mediada al menos en parte por prostaglandina d2 producida por h-pgds tal como alergia o inflamacion alergica y asma. | |
| CL2007003061A1 (es) | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. | |
| CL2007001976A1 (es) | Compuestos derivados de dioxoalcanos y dioxoalquenos; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar asma, tos, purito, hipersensibilidad. | |
| CL2007003645A1 (es) | Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria. | |
| CL2008000911A1 (es) | Compuestos derivados de pirimidina, inhibidores de prostaglandina d2; composicion farmaceutica; y uso para tratar un trastorno alergico o inflamatorio tal como rinitis alergica, asma y epoc. | |
| CL2007003804A1 (es) | Compuestos derivados de indazol; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar condiciones inflamatorias, tales como asma, epoc. | |
| BRPI0716495A2 (pt) | (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. | |
| CL2007002791A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri | |
| CL2007002904A1 (es) | Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras. | |
| CL2008000585A1 (es) | Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds. | |
| CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| CL2007002284A1 (es) | Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c. | |
| CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
| BR112012002331A2 (pt) | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica | |
| BRPI0817200A2 (pt) | composições oftálmicas sólida e uso de compostos para fabricação de medicamento | |
| CL2007003565A1 (es) | Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih. | |
| CL2008001983A1 (es) | Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras. | |
| CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
| CL2007002377A1 (es) | Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno. | |
| BRPI0720211A2 (pt) | Derivado de indanona, composição, e, uso de uma composição | |
| CL2008000060A1 (es) | Compuestos derivados de 1-carboxi-2-amida pirrolidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar fibrosis quistica, carcinoma pulmonar, bronquitis cronica, enfermedad pulmonar obstructiva cronica, asma o una inf | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
| FI20070174A0 (fi) | Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt |